Tracks Norwegian patients with borderline or locally advanced pancreatic cancer receiving chemotherapy first
Follows adults with pancreatic cancer treated with chemotherapy first, then possibly surgery.
Plain-language title generated from the registry record
Registry title: A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
Key facts
- Where
- Bergen, Oslo, Stavanger, Tromsø, and Trondheim, NorwaySee the 5 sites
Where in Norway
- Haukeland University HospitalBergen, NorwayNot yet recruiting
- Oslo University HospitalOslo, NorwayTaking people
- Stavanger University HospitalStavanger, NorwayNot yet recruiting
- University Hospital of North NorwayTromsø, NorwayNot yet recruiting
- St. Olavs Hospital, Trondheim University HospitalTrondheim, NorwayNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT06944587
- Record updated
- 25 April 2025
- Original description
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival >20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).Read full original descriptionShow less
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival >20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).
Inclusion: Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3); Nx, M0 (UICC 8th version, 2016); Cytological or histological confirmation of adenocarcinoma; Age >18 year; Considered able to receive primary chemotherapy and possible surgery; Written informed consent.
Exclusion: Co-morbidity or performance status precluding primary chemotherapy; Mental or physical disorders that could interfere with treatment of with the provision of informed consent; Female patients in child-bearing age not using adequate contraception, pregnant or lactating women; Co-morbidity or performance status precluding pancreatectomy; Any reason why, in the opinion of the investigator, the patient should not participate.